🔗 Share this article

While America proceeds with sweeping changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccines in the global health crisis and has zeroed in on potential fatalities after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Schedule

Health officials were set to announce major changes to the pediatric vaccine schedule recently, aligning the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with many the international standard with insufficient data for benefit. The planned update has been pushed back until the next year.

Instead of the top vaccines chief, Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US to become more similar to Denmark, a nation with universal health coverage and a citizenry about the population of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s CBER – instead of drug regulation.

Questions Over Background

Høeg has no obvious track record in drug development, approval processes or administrative roles, which has been standard for former leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Past heads of the center would “grasp regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who ran CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There’s a biosimilars division, over-the-counter program and more, and all of those have to be looked after,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership element to the job, which supervises over 5,000 personnel. “It’s a enormous management job, if you do it right,” Woodcock added.

Response and Controversial Policies

When asked about concerns about Dr. Høeg's credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a press secretary said that the “concerns stem from flawed presumptions”.

“Her resume matches the responsibilities of her job,” the representative said, citing the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious expedited medication authorization process that allegedly troubled her preceding directors. “How are these therapies being picked for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, with the exception of shots.”

Established History on Immunizations

Regarding immunizations, Høeg has a more documented, if problematic, history, some experts have noted. She published a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new administration featured changing guidelines for new vaccines and discontinuing “unnecessary” vaccines, she remarked following the vote on a audio program. At the FDA, Høeg has reportedly suggested barring teenage boys from getting Covid vaccinations.

“She is an thorough dogmatist who begins with her conclusions and works backwards to retrofit the science in a very disingenuous, dishonest fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|